NextPoint Therapeutics
NextPoint Therapeutics is a clinical-stage biotechnology company developing precision oncology therapeutics targeting the HHLA2 pathway. Their innovative approach integrates foundational science with a defined clinical biomarker strategy to deliver a new class of monotherapies. The company is advancing multiple assets into clinical trials to exploit HHLA2's role in both immune checkpoint and tumor-targeting.
Buy Funded Startups lists
Funding Round: Series B
Funding Amount: $122.5M
Date: 14-Feb-2024
Investors: Catalio Capital Management, MPM BioImpact, Leaps by Bayer, Sanofi Ventures, Invus, Sixty Degree Capital, Dana-Farber Cancer Institute’s Binney Street Capital, Gordon Freeman, Arkin Bio-Capital, WTT investment Ltd
Markets: Biotechnology, Oncology, Immuno-oncology, Health Care, Life Science, Therapeutics
HQ: Cambridge, Massachusetts, United States
Founded: 2020
Website: https://nextpointtx.com/
LinkedIn: https://www.linkedin.com/company/nextpoint-therapeutics
Twitter: https://twitter.com/NextPointTX
Crunchbase: https://www.crunchbase.com/organization/nextpoint-therapeutics
Leave a Comment
Comments
No comments yet.